GlassScriptPhysician profile
Lore L Garten
NPI 1376507202
$2,604.21
in general payments reported to CMS, 2019-2025
29 companies · $687 in 2025
The $687 reported for 2025 was more than what 84% of Addiction Medicine (Internal Medicine) providers received nationally (typical 2025 total: $124).
See the full distribution for Addiction Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $858 · 2020: $749 · 2021: $201 · 2023: $109 · 2025: $687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $795.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $512.99 | 2019-2020 | |
| Amgen INC. | $397.84 | 2020-2025 | Uplizna, Evenity |
| Allergan, INC. | $217.30 | 2019-2020 | |
| Indivior INC. | $149.35 | 2019-2025 | Sublocade |
| Genentech USA, INC. | $145.95 | 2019 | |
| Novo Nordisk INC | $125.00 | 2025 | Wegovy |
| Csl Behring | $114.42 | 2019-2025 | Hizentra |
| Gilead Sciences, INC. | $108.80 | 2023 | Epclusa |
| Novartis Pharmaceuticals Corporation | $79.28 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $69.07 | 2019-2021 | |
| Sk Life Science, INC. | $56.05 | 2020 | |
| Abbvie INC. | $55.82 | 2021 | |
| Grifols USA, LLC | $55.59 | 2019-2020 | |
| Alkermes, INC. | $55.42 | 2021-2025 | Vivitrol |
| Mallinckrodt Hospital Products INC. | $54.58 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Pharmaceuticals, INC. | $48.07 | 2020-2021 | |
| Braeburn INC. | $45.46 | 2025 | Brixadi |
| Ipsen Biopharmaceuticals, INC | $44.25 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $39.41 | 2020-2021 | |
| Biogen, INC. | $37.81 | 2019-2020 | |
| Livanova USA, INC. | $37.50 | 2019-2020 | |
| Greenwich Biosciences, INC. | $27.46 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $25.44 | 2019 | |
| Upsher-Smith Laboratories LLC | $21.02 | 2019 | |
| Adamas Pharmaceuticals, INC. | $18.78 | 2019 | |
| Lilly USA, LLC | $17.68 | 2020 | |
| Acorda Therapeutics, INC | $16.33 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.74 | 2021 | |
| Sunovion Pharmaceuticals INC. | $12.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lore Garten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.